Long-Term Survival Outcomes and Residual Cancer Burden Following Neoadjuvant Chemotherapy
In a pooled analysis, investigators attained participant-level residual cancer burden (RCB) results and clinical data from 12 institutes and trials in Europe and the United States. Participant-level data was examined from 5161 patients who were treated with neoadjuvant chemotherapy from September 1994 to February 2019. During follow up, 1,164 event-free survival events took place with median follow up being 56 months. Higher RCB was significantly associated with worse event-free survival. Investigators observed that the association between RCB and residual risk suggests that prospective analysis of RCB may be thought to become part of standard pathology reporting following neoadjuvant therapy.
Reference:
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149-160. doi:10.1016/S1470-2045(21)00589-1
